盘龙药业(002864) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥262,473,046.87, an increase of 18.69% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥33,099,197.05, reflecting a growth of 7.86% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.3900, up by 8.76% from the previous year[5] - Total operating revenue for Q3 2022 reached CNY 693,447,695, an increase of 11.4% compared to CNY 622,648,763.48 in the same period last year[25] - Net profit for Q3 2022 was CNY 79,940,900.98, representing a growth of 7.6% from CNY 74,619,007.52 in Q3 2021[26] - Earnings per share (EPS) increased to CNY 0.9100 from CNY 0.8542, marking a rise of 6.7%[27] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥1,807,260,234.39, representing a 35.87% increase from the end of the previous year[5] - Total assets as of the end of Q3 2022 were CNY 1,807,260,234.39, compared to CNY 1,330,174,616.17 at the end of the previous year, indicating a growth of 35.7%[24] - Total liabilities increased to CNY 884,373,441.39, up from CNY 522,967,375.29, reflecting a significant rise of 68.9%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥114,832,020.89, a rise of 39.92% compared to the same period last year[12] - Operating cash inflow for the period was $763,137,296.85, an increase of 12.83% from $676,397,253.14 in the previous period[29] - Net cash flow from operating activities was $114,832,020.89, up 39.9% compared to $82,068,441.30 in the prior period[30] - Cash inflow from financing activities reached $445,510,975.56, significantly higher than $52,522,765.54 in the previous period[31] - Net cash flow from financing activities was $317,770,977.55, compared to $13,132,383.12 in the prior period, indicating a substantial increase[31] Investments and Expenses - Research and development expenses for Q3 2022 were ¥9,157,723.10, marking a 54.86% increase year-on-year[11] - The company reported a research and development expense of CNY 9,157,723.10, which is an increase of 55.5% from CNY 5,913,641.02 in the previous year[25] - The company’s long-term equity investments reached ¥9,882,181.84, attributed to investments in the Qinlong Yaokang Fund[11] - Cash outflow for investment activities was $63,099,088.08, compared to $62,065,480.22 in the previous period, indicating a slight increase[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,817[14] - The largest shareholder, Xie Xiaolin, holds 42.88% of the shares, amounting to 37,171,000 shares[14] Stock and Incentive Plans - The company plans to grant 1,126,400 restricted shares at a price of ¥13.38 per share as part of its 2022 incentive plan[17] - The company has not completed the share registration procedures for the restricted stock incentive plan as of the report date[17] - The company issued 2,760,000 convertible bonds with a total amount of ¥276,000,000, netting approximately ¥271,984,367.92 after expenses[17] - As of September 30, 2022, 3,511 convertible bonds have been converted into 13,237 shares, representing 0.02% of the total shares outstanding[18] Current Assets - As of September 30, 2022, the company's cash and cash equivalents reached ¥788,808,577.26, an increase from ¥419,304,666.90 at the beginning of the year[21] - The total current assets as of September 30, 2022, amounted to ¥1,381,559,794.16, up from ¥956,446,085.23 at the beginning of the year[21] - Accounts receivable increased to ¥408,749,392.10 from ¥361,350,459.45, reflecting a growth of approximately 13%[21] - Inventory levels rose to ¥84,468,113.45, compared to ¥66,765,198.12, indicating a growth of about 26%[21] Future Plans - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings call[28]